Free Trial

Viatris (VTRS) News Today

Viatris logo
$8.75 +0.06 (+0.69%)
As of 02:06 PM Eastern

Why is Viatris Up Today?

Viatris Inc. (NASDAQ: VTRS) stock is trading lower today amid mounting legal overhang, partially offset by encouraging clinical data.

  • Announced positive top-line results from the Phase 3 LYNX-2 trial of MR-142 (phentolamine ophthalmic solution 0.75%) in keratorefractive patients, meeting the primary ≥15‐letter gain endpoint under FDA Special Protocol Assessment and fast-track designation.
  • A surge of securities class action lawsuits and deadline reminders has been issued by multiple law firms—including Levi & Korsinsky, Pomerantz LLP, Bronstein Gewirtz & Grossman, Bleichmar Fonti & Auld, Schall Law, Faruqi & Faruqi, Glancy Prongay & Murray, Berger Montague, Rosen and Frank R. Cruz—alleging federal securities law violations relating to disclosures from August 2024 to February 2025, with a June 3 lead plaintiff filing deadline.

Investors are weighing the potential upside from the new ophthalmic asset against the financial and reputational risks posed by ongoing litigation.

Posted 56m agoAI Generated. May Contain Errors.

VTRS Latest News

Viatris Q1 Earnings Transcript
VTRS FRAUD: Suffer Losses on Viatris Inc. ...
Get Viatris News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.

VTRS Media Mentions By Week

VTRS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VTRS
News Sentiment

0.03

0.88

Average
Medical
News Sentiment

VTRS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VTRS Articles
This Week

35

10

VTRS Articles
Average Week

Get Viatris News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:VTRS) was last updated on 6/3/2025 by MarketBeat.com Staff
From Our Partners
OSZAR »